Immuneering (NASDAQ:IMRX) Receives Buy Rating from Chardan Capital

Chardan Capital reissued their buy rating on shares of Immuneering (NASDAQ:IMRX) in a report published on Wednesday morning,Benzinga reports. They currently have a $13.00 price objective on the stock.

Separately, Needham & Company LLC reissued a “buy” rating and set a $15.00 target price on shares of Immuneering in a research note on Thursday, November 14th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $12.80.

Immuneering Stock Down 0.5 %

IMRX opened at $2.10 on Wednesday. The company’s 50-day moving average price is $2.22 and its 200 day moving average price is $1.63. Immuneering has a fifty-two week low of $1.00 and a fifty-two week high of $8.89. The firm has a market cap of $65.21 million, a price-to-earnings ratio of -1.07 and a beta of -0.40.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in IMRX. Vanguard Group Inc. lifted its position in shares of Immuneering by 12.1% during the 1st quarter. Vanguard Group Inc. now owns 1,203,666 shares of the company’s stock valued at $3,479,000 after acquiring an additional 129,851 shares during the last quarter. Acadian Asset Management LLC purchased a new stake in shares of Immuneering during the second quarter valued at $67,000. Renaissance Technologies LLC acquired a new position in shares of Immuneering in the 2nd quarter valued at $447,000. XTX Topco Ltd increased its stake in Immuneering by 37.3% in the 2nd quarter. XTX Topco Ltd now owns 34,159 shares of the company’s stock worth $44,000 after purchasing an additional 9,274 shares in the last quarter. Finally, Marshall Wace LLP acquired a new stake in Immuneering during the 2nd quarter worth about $492,000. Institutional investors and hedge funds own 67.65% of the company’s stock.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.